4DMT Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 171

Employees

  • Stock Symbol
  • FDMT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $23.95
  • (As of Wednesday Closing)

4DMT General Information

Description

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 5858 Horton Street
  • Suite 455
  • Emeryville, CA 94608
  • United States
+1 (510) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

4DMT Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.95 $24.90 $9.44 - $36.25 $1.24B 51.2M 601K -$2.44

4DMT Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,312,370 561,681 508,272 543,451
Revenue 20,471 20,723 3,129 18,038
EBITDA (115,138) (107,299) (106,187) (68,434)
Net Income (104,556) (100,837) (107,494) (71,317)
Total Assets 629,884 339,891 261,846 353,487
Total Debt 14,171 14,671 16,124 16,448
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4DMT Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates
Drug Discovery
Emeryville, CA
171 As of 2024
00000
00000000 00000

000000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo c
0000000000000
Somerville, MA
000 As of 0000
00.000
000000000 00.000

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000000000000
Berkeley, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

4DMT Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bluebird Bio Formerly VC-backed Somerville, MA 000 00.000 000000000 00.000
Caribou Biosciences Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

4DMT Patents

4DMT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022266774-A9 Compositions and methods for treatment of ocular disease associated with angiogenesis Pending 27-Apr-2021 000000000
CA-3215812-A1 Compositions and methods for treatment of ocular disease associated with angiogenesis Pending 27-Apr-2021 000000000
AU-2022266774-A1 Compositions and methods for treatment of ocular disease associated with angiogenesis Pending 27-Apr-2021 000000000
US-20240131195-A1 Compositions and methods for treatment of ocular disease associated with angiogenesis Pending 27-Apr-2021 00000000000
EP-4330411-A1 Compositions and methods for treatment of ocular disease associated with angiogenesis Pending 27-Apr-2021 C12N15/86
To view 4DMT’s complete patent history, request access »

4DMT Executive Team (17)

Name Title Board Seat Contact Info
David Kirn MD Co-Founder & Chief Executive Officer
Fariborz Kamal Ph.D Chief Operating Officer, Operations & President
Uneek Mehra Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
An Song Chief Development Officer
Scott Bizily Secretary, Administration & Chief Legal Officer, Legal
You’re viewing 5 of 17 executive team members. Get the full list »

4DMT Board Members (13)

Name Representing Role Since
Charles Theuer MD Self Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
John Milligan Ph.D Self Executive Chairman 000 0000
Nancy Miller-Rich Self Board Member 000 0000
Shawn Tomasello Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

4DMT Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4DMT Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aevitas Therapeutics 21-Apr-2023 0000000000 00000 Clinics/Outpatient Services 00000 000
To view 4DMT’s complete acquisitions history, request access »

4DMT ESG

Risk Overview

Risk Rating

Updated September, 01, 2023

27.37 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 407

Rank

00.00

Percentile

To view 4DMT’s complete esg history, request access »

4DMT FAQs

  • When was 4DMT founded?

    4DMT was founded in 2013.

  • Who is the founder of 4DMT?

    David Kirn MD, Theresa Janke, David Schaffer Ph.D, and Melissa Kotterman Ph.D are the founders of 4DMT.

  • Who is the CEO of 4DMT?

    David Kirn MD is the CEO of 4DMT.

  • Where is 4DMT headquartered?

    4DMT is headquartered in Emeryville, CA.

  • What is the size of 4DMT?

    4DMT has 171 total employees.

  • What industry is 4DMT in?

    4DMT’s primary industry is Drug Discovery.

  • Is 4DMT a private or public company?

    4DMT is a Public company.

  • What is 4DMT’s stock symbol?

    The ticker symbol for 4DMT is FDMT.

  • What is the current stock price of 4DMT?

    As of 29-May-2024 the stock price of 4DMT is $23.95.

  • What is the current market cap of 4DMT?

    The current market capitalization of 4DMT is $1.24B.

  • What is 4DMT’s current revenue?

    The trailing twelve month revenue for 4DMT is $20.5M.

  • Who are 4DMT’s competitors?

    Bluebird Bio, Caribou Biosciences, CRISPR Therapeutics, Kite Pharma, and NexImmune are some of the 47 competitors of 4DMT.

  • What is 4DMT’s annual earnings per share (EPS)?

    4DMT’s EPS for 12 months was -$2.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »